Budget impact of ferric carboxymaltose treatment in patients with chronic heart failure and iron deficiency in Spain
Por:
Delgado, J, Oliva, J, Gonzalez-Franco, A, Cepeda, J, Garcia-Garcia, J, Gonzalez-Dominguez, A, Garcia-Casanovas, A, Merino, S and Comin-Colet, J
Publicada:
1 dic 2020
Ahead of Print:
1 oct 2020
Categoría:
Health policy
Resumen:
Objective
The treatment of iron deficiency (ID) with ferric carboxymaltose (FCM) improves the functional class and quality of life of chronic heart failure (CHF) patients with reduced left ventricular ejection fraction (LVEF), and reduces the rate of hospitalization due to worsening CHF. This study aims to evaluate the budget impact for the Spanish National Health System (SNHS) of treating ID in reduced LVEF CHF with FCM compared to non-iron treatment.
Methods
We simulated a hypothetical cohort of 1000 CHF patients with ID and reduced LVEF based on the Spanish population characteristics. A decision-analytic model was also built using the data from the largest FCM clinical trial (CONFIRM-HF) that lasted for a year. We considered the use of healthcare resources from a national prospective study. A deterministic sensitivity analysis was carried out varying the corresponding baseline data by +/- 25%.
Results
The cost of treating the simulated population with FCM was euro2,570,914, while that of the non-iron treatment was euro3,105,711, which corresponds to a cost saving of euro534,797 per 1,000 patients in one year. Cost savings were mainly due to a decrease in the number of hospitalizations. All sensitivity analysis showed cost savings for the SNHS.
Conclusions
FCM results in an annual cost saving of euro534.80 per patient, and would thus be expected to reduce the economic burden of CHF in Spain.
Filiaciones:
Delgado, J:
Hosp Univ 12 Octubre, Cardiol Serv, Ctr Investi Red Enfermedades Cardiovasc CIBERCV, Avda Cordoba Sn, Madrid 28041, Spain
Univ Complutense Madrid, Fac Med, Madrid, Spain
Oliva, J:
Univ Castilla La Mancha, Dept Econ Anal, Toledo, Spain
Gonzalez-Franco, A:
Hosp Univ Cent Asturias, Dept Internal Med, Asturias, Spain
Spanish Soc Internal Med SEMI, Heart Failure & Atrial Fibrillat Grp, Madrid, Spain
:
Hosp Vega Baja de Orihuela, Dept Internal Med, Alicante, Spain
Garcia-Garcia, J:
Hosp Univ Virgen del Valme, Dept Internal Med, Seville, Spain
Gonzalez-Dominguez, A:
Weber, Madrid, Spain
Garcia-Casanovas, A:
Hosp Mar Med Res Inst IMIM, Barcelona, Spain
Merino, S:
Vifor Pharma, Barcelona, Spain
Comin-Colet, J:
Hosp Univ Bellvitge, Community Heart Failure Program, Dept Cardiol, Bellvitge Biomed Res Inst IDIBELL, Barcelona, Spain
Univ Barcelona, Barcelona, Spain
Green Published, hybrid
|